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| INTRODUC TI ON
Mast cells play a significant role in asthma through their activation and production of mediators with pro-inflammatory and airway constrictive effects, 1 and perhaps even more so in severe 2 or uncontrolled asthma. 3 Asthmatic patients have an increased number of mast cells at particular sites of the lung such as in the airway smooth muscle, 4 in the bronchial epithelium 5 and in the alveolar parenchyma. 3 Haematopoietic stem cells and progenitors in the bone marrow can give rise to tissue-resident mast cells. 6 Human mast cells have been derived in vitro from peripheral or cord blood for many years. 7 However, we recently identified a population of mast cell progenitors (MCp) in the blood circulation as CD4 − CD8 − CD19 − CD14 − CD34 hi CD117 + FcεRI + cells, thus allowing the quantification and characterization of this rare population in healthy and diseased individuals. 8 Previous studies in mice using a sensitization and challenge model addressed the mechanism behind the expansion of lung mast cells in asthma. The antigen-induced inflammation caused a strong influx of bone marrow-derived MCp from the blood to the lung, which was inhibited by antibodies blocking alpha 4 integrins and VCAM-1, or genetic deletion of endothelial VCAM-1. 9 At later timepoints after the induction of allergic lung inflammation, an increased number of mast cells were demonstrated in the tracheal epithelium 10 and in the alveolar parenchyma. 11 Therefore, the increase in lung mast cells in asthmatic patients is likely due to the recruitment of circulating MCp to the lung followed by in situ maturation into mast cells. In our view, an active recruitment of MCp from the bone marrow to the lung via the blood should be reflected in an increased frequency of blood MCp.
In the present study, our aim was to explore the possible relationship between MCp frequency and asthma outcomes as well as both established and novel markers of inflammation in a group of young adults with allergic asthma and controls.
| MATERIAL S AND ME THODS

| Subjects
Blood samples were obtained from 67 individuals (38 subjects with allergic asthma and 29 controls), aged 15-41 years, in a follow-up study of the MIDAS cohort (Minimally Invasive Diagnostic Procedures in Allergy, Asthma, or Food Hypersensitivity Study).
The inclusion criteria for asthmatic patients in MIDAS were physician-diagnosed asthma and daily treatment with an inhaled corticosteroid (ICS) and/or an oral leukotriene receptor antagonist (LTRA) during at least three of the past 12 months before the first MIDAS. 12 The control subjects were considered non-atopic (<0.35 kU A /L in Phadiatop and fx5; ImmunoCAP) when tested 3-5 years prior to the present study, and did not have an asthma diagnosis. In an interim analysis, the MCp frequency and the percent predicted forced expiratory volume in 1 second (FEV 1 ) of a few of the subjects (13 allergic asthmatic patients and 10 controls) were reported previously. 8 
| Asthma outcomes
The Asthma Control Test (ACT) was used to determine the degree of asthma control. Spirometry was performed according to ATS/ERS guidelines, 13 and the highest values of three acceptable measurements for FEV 1 , forced vital capacity (FVC), and peak expiratory flow (PEF) were used for the analyses. Forced expiratory flow (FEF) rates at 25%, 50% and 75% of vital capacity exhaled were calculated from the curve with the highest sum of FEV 1 and FVC. For subjects less than 18 years of age (13 subjects), Solymar reference values were used, 14 whereas Hedenström reference values were used for subjects 18 years or older. 15 The fraction of exhaled nitric oxide (FeNO) was measured according to the American Thoracic Society/European Respiratory Society recommendations 12 using a chemiluminescence analyser (NIOX Flex; Aerocrine AB, Solna, Sweden).
| Blood measurements
Total serum IgE was measured using the ImmunoCAP system (Immunodiagnostics, Thermo Fisher Scientific, Uppsala, Sweden).
One negative value obtained for total IgE was omitted. Blood cells were counted at the Department of Clinical Chemistry and Pharmacology at Uppsala University Hospital using a routine method (Cell-Dyn Sapphire, Abbott, Illinois, USA) for 62 out of 67 subjects.
The Inflammation and the Immune response panels from Olink Proteomics (Uppsala, Sweden) were used to quantify 180 different proteins in EDTA plasma by the proximity extension and ligation method. 16 For the complete lists of the analysed proteins, see the 
| Mononuclear cell enrichment
The blood was collected in EDTA-treated tubes (12-15 mL; BD Vacutainer, BD Bioscience, Franklin Lakes, NJ). Peripheral blood mononuclear cells (PBMC) were enriched using Ficoll-Paque Premium (ρ = 1.076 g/mL) (GE Healthcare, Little Chalfont, UK) in SepMate™-50 tubes (Stemcell Technologies, Vancouver, Canada).
Platelets were removed by centrifugation (2 × 200 g, 10 minutes).
| Flow cytometry
To quantify human MCp, 10 × 10 6 enriched mononuclear cells were incubated in PBS, pH 7.4 with 2% heat-inactivated fetal calf serum (Sigma-Aldrich, St. Louis, MO) with the following fluorescent-labelled antibodies; CD4 (RPA-T4), CD8 (RPA-T8), CD13 (WM15), CD14 (M5E2), CD19 (HIB19), CD34 (581), CD117 (104D2) and FcεRI (AER-37). The antibodies were obtained from BD Bioscience and eBioscience, San Diego, CA, USA. The flow cytometry was performed on a LSRII, LSRFortessa or a FACSAria III (BD Biosciences). Data analysis was performed using FlowJo software version 9.8. 
| Data analyses
| Ethical statement
All subjects gave their written informed consent to participate in the study, which was approved by the Uppsala Regional Ethics Review Board (Dnr 2012/420).
| RE SULTS
| Subject characteristics and quantification of blood mast cell progenitors
Blood from 38 allergic asthmatic patients and 29 controls of similar age, height, weight and body mass index ( Table 1) asthmatic patients, but not in the controls (Figure 2A ). This relation was consistent when dividing all subjects or allergic asthmatic patients into two groups according to the median FEV 1 (90% of predicted; Figure S1A,B) . The analysis demonstrated that subjects with reduced lung function had a higher frequency of MCp in their blood circulation (P = 0.001) ( Figure S1A ). This association was also found among the allergic asthmatic patients (P = 0.003) ( Figure S1B ).
| The frequency of circulating mast cell progenitors is higher in women and subjects with reduced lung function
Furthermore, MCp frequency correlated negatively with peak ex- When all subjects were grouped according to gender, women had a mean FEV 1 (% of predicted) of 89 ± 11, which was lower than the mean for men (95 ± 13; Figure S1C ). Women also had a trend to a lower PEF (% of predicted) than men ( Figure S1D ). When the MCp frequency was compared between genders, women with allergic asthma had higher mean frequency of MCp/L blood than men ( Figure 2C ), and the same relationship was demonstrated among all subjects ( Figure S1E ). These differences remained significant after adjustment for FEV 1 . However, in the controls, women and men had a similar mean MCp frequency ( Figure 2D ). Further, the association between lung function and MCp frequency within each gender was investigated. In women, there was also a trend towards a correlation between FEV 1 (% of predicted; P = 0.08) and MCp frequency ( Figure   S1F ), and there was a correlation between PEF (% of predicted; P = 0.005) and frequency of MCp ( Figure S1H ). However, such correlations were not found in men ( Figure S1G ,I).
| The expression of FcεRI on mast cell progenitors is higher in allergic asthmatic patients and correlates with the level of total IgE in controls
The allergic asthmatic patients had ~11 times higher total IgE than the controls (Table 1) . On average, the allergic asthmatic patients had a higher geometric mean fluorescence intensity (gMFI) of FcεRI on the MCp than the controls ( Figure 3A) . When the gMFI of the FcεRI expression on the MCp was compared to the level of total IgE, a positive correlation was found among all subject (P = 0.002) and the controls (P < 0.0001) ( Figure 3B) . However, such a correlation was not found in the allergic asthmatic patients (P = 0.64). In addition, there was no association between the level of total IgE and the frequency of circulating MCp ( Figure 3C ), FEV 1 (% of predicted) or gMFI of the FcεRI expression on the MCp (not shown).
| FGF-21 levels correlate positively with the frequency of circulating mast cell progenitors in allergic asthmatic patients
The concentration of 180 different inflammation-and immune-related proteins in plasma was determined using two proximity ligation assay panels. Eight proteins correlated with MCp/L blood using a model of linear regression with adjustment for age and gender ( Table 2 ). After adjustment for multiple testing (Benjamini-Hochberg), the level of fibroblast growth factor 21 (FGF-21) remained correlated with the frequency of MCp/L blood. FGF-21 also remained significant when using the more conservative Bonferroni correction for multiple testing.
Next, the subjects were divided into allergic asthmatic patients and controls, and correlation analyses for the three top hits level of FGF-21, and DCBLD2 were found in allergic asthmatic patients, but not in the controls (Figure 4 ). The level of HNMT showed a trend to be positively correlated with MCp frequency in both allergic asthmatic patients and controls ( Figure S2A,B ). Since the MCp frequency correlated with reduced lung function, we tested whether a correlation between FGF-21, HNMT or DCBLD2 and FEV 1 (% of predicted) could be found. Both FGF-21 and DCBLD2 levels correlated negatively with FEV 1 in all subjects (Figure 4E,F 
| D ISCUSS I ON
In this study, the frequency of circulating MCp correlated with reduced FEV 1 , PEF, FEF 25 and FEF 50 (% predicted) among the allergic asthmatic patients, suggesting that a moderately reduced lung function among well-controlled asthmatic patients may reflect pathological changes due to mast cell infiltration. Indeed, several studies using experimental models of asthma and mice deficient in mast cells [17] [18] [19] or specific mast cell mediators, for example tryptase (mMCP-6), 20 have demonstrated that lung function is the main asthma outcome related to mast cells. MCp are recruited to the lung in similar experimental mouse models, leading to an expanded mast cell population at particular sites of the lung, 6 as also observed in asthmatic patients. 4, 5 Thus, a high frequency of circulating MCp may be a sign of mast cell-driven decline in lung function.
In the present study, allergic asthmatic patients and controls had a variable but on average similar frequency of blood MCp.
The explanation to this may be that the majority of the allergic asthmatic patients in the study had relatively normal lung function (the median FEV 1 was 91.5% of predicted), well-controlled asthma (mean Asthma Control Test (ACT) of 21 ± 2.9), ongoing asthma treatment and were investigated when their asthma was stable.
Worth noting is that the four highest MCp frequencies detected were among the controls. When the controls were subgrouped according to their self-reported health issues, two of the four control subjects with the highest MCp frequency reported respiratory problems (none of the controls were treated with inhaled corticosteroids). We recently found that during acute influenza infection in mice, innate immunity triggers the recruitment of MCp to the lung to a similar extent as allergic inflammation. 21, 22 The individuals included in our study had to be free from cold symptoms 2 weeks prior to the clinic visit. However, some may have had a prior or subclinical respiratory infection that caused the higher levels of circulating MCp, and possibly could explain a slightly reduced lung function in the controls.
As reviewed by Postma, 23 the prevalence of asthma is higher in boys during childhood, whereas after puberty the prevalence is higher in women. When the young adults in our study were grouped according to gender, a higher mean frequency of circulating MCp was found among women, and this relationship was strongest among the allergic asthmatic patients. Although adult men have larger airways, especially trachea, than women, 24 adjustment for gender is part of the calculation for FEV 1 (% of predicted), despite this there is a difference in FEV 1 between the genders in this study. Future investigations will tell whether the gender difference in MCp frequency is general or related to this cohort.
Asthma is associated with high total IgE levels, independently of the presence of IgE sensitization. 25, 26 Moreover, the biology of mast cells is tightly connected to the expression of FcεRI and the binding of IgE to this receptor enhances the expression in mice. 27 To determine whether a similar relationship exists in human MCp, to control mice given the same dose of antigen alone in a process dependent on an Fc receptor associated with the FcRγ chain, possibly FcεRI. 28 Thus, another avenue to explore would be to test whether allergic asthmatic patients acutely exposed to the allergen they are sensitized to have an increased frequency of circulating MCp during exposure compared to when they are not exposed.
In our efforts to obtain a non-biased clue to the molecular mechanisms behind having a high frequency of circulating MCp, FGF-21 was identified as the single plasma protein (out of 180) that correlated significantly with MCp frequency in all subjects after the adjustment for multiple testing. FGF-21 is a soluble protein with effects on glucose and lipid metabolism. 29 Assuming that a high MCp frequency implies recruitment of MCp to the lung, a possible connection between MCp frequency and FGF-21 is the lipid mediators leukotriene B4 and prostaglandin D2, which have been shown to attract in vitro-derived MCp to the skin of mice. 30 In subanalyses of allergic asthmatic patients and controls, the three proteins that had the lowest adjusted p-values after multiple testing were investigated. In the allergic asthmatic patients, FGF-21 and DCBLD2 were identified to positively correlate with the frequency of circulating MCp. DCBLD2 is a transmembrane protein expressed in vascular endothelial and smooth muscle cells, and associations between DCBLD2 haplotypes and a decline in FEV 1 following aspirin challenge were found in aspirin-exacerbated respiratory disease (AERD). 31 AERD is more common among women and young adults, and mast cells and lipid mediators such as cysteinyl-leukotrienes and prostaglandin D2 are implicated in the pathogenesis. 32 Thus, the relationship between DCBLD2 levels and MCp frequency is intriguing. Worth noting is that both FGF-21 and DCBLD2 levels correlated negatively with FEV 1 in all subjects and in the controls, while in the allergic asthmatic patients, the negative correlation between FGF-21 and FEV 1 showed only a trend, and was not at all observed between DCBLD2 and FEV 1 . Hence, whereas the relationship between MCp frequency and FEV 1 was significant only among the allergic asthmatic patients, FGF-21 and DCBLD2 levels were related to reduced FEV 1 in general. Further studies are needed to clarify the relationships between the MCp frequency, plasma levels of FGF-21 and DCBLD2 and FEV 1 .
To conclude, a high frequency of circulating MCp correlates with reduced lung function, implying ongoing recruitment of MCp to the lung, and perhaps indicating mast cell involvement in declining lung function. The finding regarding higher levels of circulating MCp in women with allergic asthma is interesting from disease mechanism point of view, but should be replicated in other patient populations. 
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